Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT

CompletedOBSERVATIONAL
Enrollment

61

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Allogeneic Haematopoietic Stem Cell Transplantation
Interventions
DRUG

Treosulfan

Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged \< 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged \> 12 months)

Trial Locations (2)

WC1N 3JH

Great Ormond Street Hospital for Children, London

NE1 4LP

Great North Childrens Hospital, Newcastle upon Tyne

All Listed Sponsors
collaborator

Newcastle-upon-Tyne Hospitals NHS Trust

OTHER

lead

Great Ormond Street Hospital for Children NHS Foundation Trust

OTHER

NCT02048800 - Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT | Biotech Hunter | Biotech Hunter